The Hepatitis C Treatment Information Project just received an advance notification from BC’s Ministry of Health that Sunvepra (asunaprevir) and Daklinza (daclatasvir)** will soon be considered for BC PharmaCare coverage. The tentative dates for input into this process are from Wednesday June 17, 2015 to midnight on Wednesday July 15, 2015*.
If you are a BC resident and answer yes to any of the following questions, you can give your input into whether or not the treatments should be covered by PharmaCare:
- Do you have hep C?
- Are you a caregiver to someone who has hep C?
- Does your patient group represent patients who have hep C AND have you registered with PharmaCare to give input? (Learn more about registering your organization).
Please note that PharmaCare’s questionnaire for Sunvepra and Daklinza input tentatively wont be available for another two weeks. The Hepatitis C Treatment Information Project will follow this development and keep you updated.
Additional information about Sunvepra (asunaprevir) and Daklinza (daclatasvir) can be found at Asunaprevir and Daclatasvir Advance, a blog post written in January when the Canadian Agency for Drugs and Technologies in Health (CADTH) began reviewing the treatments.
*This process for Sunvepra (asunaprevir) and Daklinza (daclatasvir) has been rescheduled by BC PharmaCare until possibly the end of July. Please see Advance Notice for Sunvepra and Daklinza 2 for more information.
**Sunvepra (asunaprevir) and Daklinza (daclatasvir) have not yet received Notices of Compliance from Health Canada. They still can not be bought in Canada and are still being reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH). Click here for more information about the drug approval process.